Belite Bio News

Belite Bio Unveils Plan to Offer 651,380 American Depository Shares

Belite Bio (BLTE) said late Thursday it is planning to sell up to 651,380 American depositary shares at $38.38 per ADS in a registered direct offering. The company also plans to sell warrants to purch

MT NewswiresApr 26 06:21 ET

Belite Bio Prices $25M Direct Offering

Seeking AlphaApr 26 05:02 ET

Reported Earlier, Belite Bio Secures $25M In Registered Direct Offering With Institutional Investors

Belite Bio entered into a securities purchase agreement with an institutional investor, for the purchase and sale of up to an aggregate of 651,380 American Depositary Shares of the Company ("ADSs"), e

BenzingaApr 26 03:03 ET

Express News | Belite Bio Announces $25 Million Registered Direct Offering

ReutersApr 25 19:15 ET

Belite Bio Is Maintained at Buy by HC Wainwright & Co.

Belite Bio Is Maintained at Buy by HC Wainwright & Co.

Dow JonesMar 22 11:23 ET

Express News | HC Wainwright & Co. Maintains Buy on Belite Bio, Maintains $59 Price Target

Moomoo 24/7Mar 22 11:13 ET

Buy Rating Affirmed on Belite Bio as Tinlarebant Shows Promising Clinical Advancements and Market Potential

TipRanksMar 22 09:25 ET

Belite Bio Advances Retinal Disease Treatment

TipRanksMar 22 08:27 ET

Belite Bio Announces PMDA Submission of Tinlarebant for Stargardt Disease Clinical Trial in Japan

Tinlarebant is Belite Bio's orally administered tablet intended to slow disease progression in patients affected with Stargardt Disease (STGD1) and Geographic Atrophy (GA) in advanced Dry Age-related Macular Degeneration

GlobeNewswireMar 22 08:00 ET

Buy Rating Justified for Belite Bio, Inc. ADR Amidst Promising DRAGON Trial Progress and Strong Financials

TipRanksMar 21 02:16 ET

We're Hopeful That Belite Bio (NASDAQ:BLTE) Will Use Its Cash Wisely

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and mining exploration companies often lose money for years before finding success wi

Simply Wall StMar 20 08:59 ET

Here's Why We're Not Too Worried About Belite Bio's (NASDAQ:BLTE) Cash Burn Situation

Yahoo FinanceMar 20 07:32 ET

Analysts Offer Insights on Healthcare Companies: Belite Bio, Inc. ADR (BLTE), Arcellx Inc (ACLX) and AdaptHealth (AHCO)

TipRanksMar 18 07:10 ET

Analysts' Top Healthcare Picks: Belite Bio, Inc. ADR (BLTE), Catalyst Pharma (CPRX)

TipRanksMar 14 07:40 ET

Analysts Offer Insights on Healthcare Companies: Crinetics Pharmaceuticals (CRNX), Belite Bio, Inc. ADR (BLTE) and Prothena (PRTA)

TipRanksMar 13 06:20 ET

Earnings Call Summary | Belite Bio(BLTE.US) Q4 2023 Earnings Conference

The following is a summary of the Belite Bio, Inc (BLTE) Q4 2023 Earnings Call Transcript:Financial Performance:No financial performance details provided during the earnings call.Business Progress:Bel

moomoo AIMar 12 21:05 ET · Conference Call

Belite Bio's Q4 Loss Narrows

Belite Bio (BLTE) reported late Monday a Q4 net loss of $0.25 per ordinary share, compared with the $0.27 loss per share a year earlier. Five analysts polled by Capital IQ expected a loss of $0.30 per

MT NewswiresMar 12 04:43 ET

Belite Bio GAAP EPS of -$0.25 Beats by $0.05

Seeking AlphaMar 12 01:13 ET

Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website

SAN DIEGO, March 11, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerati

GlobeNewswireMar 11 22:28 ET

Belite Bio 4Q Loss/Shr $0.25 Vs. Loss $0.27 >BLTE

Belite Bio 4Q Loss/Shr $0.25 Vs. Loss $0.27 >BLTE

Dow JonesMar 11 21:35 ET